134 related articles for article (PubMed ID: 38419316)
1. Significance of Continuous Low-Dose Lenvatinib for the Treating of the Patients with Unresectable Thyroid Carcinoma.
Murakami D; Nishimoto K; Takao S; Miyamaru S; Kadowaki T; Saito H; Takeda H; Ise M; Suyama K; Orita Y
Acta Med Okayama; 2024 Feb; 78(1):63-70. PubMed ID: 38419316
[TBL] [Abstract][Full Text] [Related]
2. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
[TBL] [Abstract][Full Text] [Related]
3. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
4. Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients.
Fukuda N; Toda K; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocr J; 2021 Jun; 68(6):639-647. PubMed ID: 33504716
[TBL] [Abstract][Full Text] [Related]
5. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
6. Factors involved in early lenvatinib dose reduction: a retrospective analysis.
Suyama K; Tomiguchi M; Takeshita T; Sueta A; Yamamoto-Ibusuki M; Shimokawa M; Yamamoto Y; Iwase H
Med Oncol; 2018 Jan; 35(3):19. PubMed ID: 29387983
[TBL] [Abstract][Full Text] [Related]
7. Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study.
Lee EK; Kim SM; Kim BH; Kim MJ; Lim DJ; Kim MH; Shin DY; Kang HC; Ahn BC; Kim SW; Ahn HY; Park YJ
Thyroid; 2019 Dec; 29(12):1811-1819. PubMed ID: 31482759
[No Abstract] [Full Text] [Related]
8. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
9. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
[No Abstract] [Full Text] [Related]
10. Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?
Lorusso L; Newbold K
Future Oncol; 2015; 11(12):1719-27. PubMed ID: 26075440
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
[No Abstract] [Full Text] [Related]
12. Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
Nervo A; Ragni A; Gallo M; Ferraris A; Fonio P; Piovesan A; Arvat E
Thyroid; 2020 Feb; 30(2):229-236. PubMed ID: 31854230
[No Abstract] [Full Text] [Related]
13. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.
Kiyota N; Schlumberger M; Muro K; Ando Y; Takahashi S; Kawai Y; Wirth L; Robinson B; Sherman S; Suzuki T; Fujino K; Gupta A; Hayato S; Tahara M
Cancer Sci; 2015 Dec; 106(12):1714-21. PubMed ID: 26426092
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
Tori M; Shimo T
BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials.
Yan Z; Yang M; Lai CL
Clin Endocrinol (Oxf); 2021 Sep; 95(3):478-488. PubMed ID: 33834514
[TBL] [Abstract][Full Text] [Related]
16. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
[TBL] [Abstract][Full Text] [Related]
17. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.
Zheng X; Xu Z; Ji Q; Ge M; Shi F; Qin J; Wang F; Chen G; Zhang Y; Huang R; Tan J; Huang T; Li S; Lv Z; Lin Y; Guo Z; Kubota T; Suzuki T; Ikezawa H; Gao M
Clin Cancer Res; 2021 Oct; 27(20):5502-5509. PubMed ID: 34326132
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Schlumberger M; Jarzab B; Cabanillas ME; Robinson B; Pacini F; Ball DW; McCaffrey J; Newbold K; Allison R; Martins RG; Licitra LF; Shah MH; Bodenner D; Elisei R; Burmeister L; Funahashi Y; Ren M; O'Brien JP; Sherman SI
Clin Cancer Res; 2016 Jan; 22(1):44-53. PubMed ID: 26311725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]